Evidence mapPaperPMID 28384260Full record

ArticlePLoS pathogens2017

DENV up-regulates the HMG-CoA reductase activity through the impairment of AMPK phosphorylation: A potential antiviral target.

Rubén Soto-Acosta, Patricia Bautista-Carbajal, Margot Cervantes-Salazar, Antonio H Angel-Ambrocio, Rosa M Del Angel

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04377451 (Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue), which is not on this map. Cited by 74 papers.

0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed
9.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04377451 phase1 / phase2completedstarted 2020, after this paper: background citation

Metformin as Adjunctive Therapy in Overweight and Obese Patients With Dengue: an Open-label Safety and Tolerability Trial

Ran2020Enrolled120Registered outcomes7Posted comparisons0ConditionsAnti-inflammatory Agents, Dengue, Metformin, ObesityArmsMetformin
Open the trial in the graph
3 · Its place in the literature

Who cites it

74 citing papers in PubMed, 126 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

14 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Rubén Soto-AcostaDepartmento de Infectómica y Patogénesis Molecular, CINVESTAV-IPN, México, D.F., México.
Patricia Bautista-CarbajalDepartmento de Infectómica y Patogénesis Molecular, CINVESTAV-IPN, México, D.F., México.
Margot Cervantes-SalazarDepartmento de Infectómica y Patogénesis Molecular, CINVESTAV-IPN, México, D.F., México.
Antonio H Angel-AmbrocioDepartmento de Infectómica y Patogénesis Molecular, CINVESTAV-IPN, México, D.F., México.
Rosa M Del AngelDepartmento de Infectómica y Patogénesis Molecular, CINVESTAV-IPN, México, D.F., México.ORCID http://orcid.org/0000-0002-6785-2035
Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional · MXThe University of Texas Medical Branch at Galveston · US

Funding

NIAID NIH HHS R01 AI101431
6 · The paper itself

Abstract

Dengue is the most common mosquito-borne viral disease in humans. Changes of lipid-related metabolites in endoplasmic reticulum of dengue virus (DENV) infected cells have been associated with replicative complexes formation. Previously, we reported that DENV infection inhibits HMGCR phosphorylation generating a cholesterol-enriched cellular environment in order to favor viral replication. In this work, using enzymatic assays, ELISA, and WB we found a significant higher activity of HMGCR in DENV infected cells, associated with the inactivation of AMPK. AMPK activation by metformin declined the HMGCR activity suggesting that AMPK inactivation mediates the enhanced activity of HMGCR. A reduction on AMPK phosphorylation activity was observed in DENV infected cells at 12 and 24 hpi. HMGCR and cholesterol co-localized with viral proteins NS3, NS4A and E, suggesting a role for HMGCR and AMPK activity in the formation of DENV replicative complexes. Furthermore, metformin and lovastatin (HMGCR inhibitor) altered this co-localization as well as replicative complexes formation supporting that active HMGCR is required for replicative complexes formation. In agreement, metformin prompted a significant dose-dependent antiviral effect in DENV infected cells, while compound C (AMPK inhibitor) augmented the viral genome copies and the percentage of infected cells. The PP2A activity, the main modulating phosphatase of HMGCR, was not affected by DENV infection. These data demonstrate that the elevated activity of HMGCR observed in DENV infected cells is mediated through AMPK inhibition and not by increase in PP2A activity. Interestingly, the inhibition of this phosphatase showed an antiviral effect in an HMGCR-independent manner. These results suggest that DENV infection increases HMGCR activity through AMPK inactivation leading to higher cholesterol levels in endoplasmic reticulum necessary for replicative complexes formation. This work provides new information about the mechanisms involved in host lipid metabolism during DENV replicative cycle and identifies new potential antiviral targets for DENV replication.

Indexed as

AMP-Activated Protein KinasesAnimalsAntiviral AgentsCell LineDengueDengue VirusGenome, ViralHumansHydroxymethylglutaryl CoA ReductasesPhosphorylationTranscriptional ActivationUp-RegulationVirus ReplicationAMP-Activated Protein KinasesAntiviral AgentsHMGCR protein, humanHydroxymethylglutaryl CoA Reductases

Identifiers

PMID28384260
PMCPMC5383345
OpenAlexW2604581406

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.